Physician profile
Tara E Degnan
NPI 1023665460
$4,940.69
in general payments reported to CMS, 2019-2025
24 companies · $2,195 in 2025
The $2,195 reported for 2025 was more than what 94% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $97.60 · 2023: $1,130 · 2024: $1,518 · 2025: $2,195.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,798 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,798.09 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,416.84 | 2023-2025 | |
| Novo Nordisk INC | $866.48 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $754.24 | 2022-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $539.63 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $387.25 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astellas Pharma US INC | $166.32 | 2023-2025 | Veozah |
| Amgen INC. | $141.99 | 2023-2025 | Evenity, Repatha, Prolia |
| Exact Sciences Corporation | $81.62 | 2025 | Cologuard Collection Kit |
| Edwards Lifesciences Corporation | $77.55 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $76.61 | 2022-2024 | Combivent Respimat, Stiolto Respimat, Spiriva Respimat |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $60.00 | 2025 | Caplyta |
| Dexcom, INC. | $53.99 | 2025 | Dexcom G6 Transmitter |
| Pfizer INC. | $43.05 | 2023-2024 | |
| Pulmonx Corporation | $41.14 | 2023 | Zephyr Endobronchial Valve, Chartis Catheter, Pulmonx Chartis Tablet Console |
| Phathom Pharmaceuticals, INC. | $36.70 | 2024-2025 | Voquezna |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $35.15 | 2025 | Zoryve |
| Otsuka America Pharmaceutical, INC. | $28.94 | 2025 | Rexulti |
| Amneal Pharmaceuticals LLC | $25.32 | 2025 | Unithroid |
| Seqirus USA INC | $20.90 | 2025 | Flucelvax, Fluad |
| Xeris Pharmaceuticals, INC. | $19.61 | 2025 | Gvoke Hypopen |
| Kyowa Kirin, INC. | $19.41 | 2025 | |
| Novartis Pharmaceuticals Corporation | $19.33 | 2024 | |
| Inari Medical, INC. | $15.25 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Merck Sharp & Dohme LLC | $13.37 | 2024 | Gardasil, Vaxelis, Gardasil 9 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tara Degnan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.